China Resources Double-Crane Pharmaceutical Co.Ltd(600062) with a market value of nearly 30 billion raised the limit again today, and achieved seven days and four boards . For a longer time, the cumulative maximum increase since the low of 11.29 yuan on March 16 is 125%.
What funds are behind “making waves” China Resources Double-Crane Pharmaceutical Co.Ltd(600062) one day list data released after hours showed that the capital of longhubang sold 497709 million yuan net, quantitative Fund ranked buy one and sell five seats, bought 151 million yuan and sold 514901 million yuan Shanghai Stock connect ranked the buy five and sell three seats, buying 525795 million yuan and selling 805541 million yuan. China stock market news securities, known as “retail base” , bought four seats in Lhasa, and bought 549508 million yuan
After hours today, China Resources Double-Crane Pharmaceutical Co.Ltd(600062) disclosed the announcement on the change of stock price. Recently, it was rumored that the covid-19 oral drug azvudine of Henan real biology was about to be blinded, up to now, the company has not reached a relevant agreement with Henan real biology
According to public information, aztudine is a new nucleoside antiviral drug originally developed for the treatment of AIDS. In April 2020, SFDA was approved by the COVID-19 phase three clinical trial. At present, the phase III clinical trial has been completed, and the results of Russia and Brazil have been submitted for approval.
On April 16 this year, Jiang Jiandong, academician of the Chinese Academy of engineering, focused on the clinical efficacy of the real biological azvudine, has similar therapeutic effects on severe and mild patients patients turned negative after oral administration for 3-4 days, with an average of 6-7 days and an average of 9 days.
Under the expectation of azvudine phase III clinical data Unblinding results , azvudine industry chain related companies have also attracted capital attention.
From the perspective of China Resources Double-Crane Pharmaceutical Co.Ltd(600062) fundamentals, on the one hand, the company has the ability to produce and manufacture chemical drugs. On October 20, 2021, China Resources Double-Crane Pharmaceutical Co.Ltd(600062) reached an agreement with ligand pharmaceutical company, jointly developed an oral small molecule RNA polymerase inhibitor for covid-19 (currently in preclinical stage), and used ligand’s bepro technology to improve the oral administration efficacy of nucleoside antiviral drugs.
On the other hand, backed by the parent company China Resources pharmaceutical, it has strong pharmaceutical circulation and retail channels in China as a support.
At the end of the year, the highest increase in the year was 2433%. At the end of the year, the highest rate of the year at the end of the year at the end of the year at the end of the year at the end of the year at the end of the year at the end of the year at the end of the year at the end of the year at the end of the year at the end of the year at the end of the year at the end of the The operation of the new production line still needs the approval of relevant competent departments, and the production time is uncertain. Xinxiang pharmaceutical has been supplied to real organisms in 2022, and currently has no orders in hand
Zhejiang Ausun Pharmaceutical Co.Ltd(603229) (the highest increase in the year was 142%) mainly engaged in the R & D and production of characteristic APIs and pharmaceutical intermediates. Beijing Xiehe pharmaceutical factory, one of the company’s top five customers, can produce azvudine tablets company’s prospectus shows that Beijing Xiehe Pharmaceutical Co., Ltd. is its top five customers and sells CS acid, entecavir and other products to it, of which CS acid is only sold to Beijing Xiehe Pharmaceutical Co., Ltd. CS acid is an important intermediate for the synthesis of besenol. Entecavir is a guanine nucleoside analogue, which is similar to azvudine in structure.
It is worth noting that Zhejiang Ausun Pharmaceutical Co.Ltd(603229) said in the announcement of share price changes disclosed on April 13 that it had recently paid attention to media reports and listed the company as covid-19 concept stock. After verification, company has no covid-19 drug-related products at present
Recently, good news came from three domestic covid-19 specific drugs. Vv116 of Shanghai Junshi Biosciences Co.Ltd(688180) is the second domestic covid-19 specific drug to publicly disclose R & D data recently. Previously, Kaifa pharmaceutical announced the global multicenter phase III clinical data of prochloramide in the treatment of non hospitalized covid-19 patients with mild and moderate diseases, and said it would actively apply to China, the United States and other countries for emergency medication EUA license.
For the three covid-19 specific drugs who can be approved to market first / the treatment effect is the best , institutional analysts told the associated press that it is difficult to draw a conclusion until the phase III clinical data are disclosed
